Send to printer »

GEN News Highlights : Oct 15, 2009

Sangretech Gives Bostwick Scientific Rights to Its Dendritic-Cell Technology

Sangretech Biomedical will provide Bostwick Scientific with exclusive rights to its dendritic-cell technology in certain territories. Sangretech’s technology will be used in the development and commercialization of VDC2008, Bostwick Scientific’s clinical-stage product candidate employing unloaded or virgin dendritic cells in combination with cryotherapy and other primary therapies to potentially treat prostate and other solid cancers.